drugset / Trial / NCT07397325
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Phase 1/2
Not yet recruiting
60 enrolled
Applied Biology, Inc.
Daniel Alain, Inc. · collabFollea International Limited · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
Timeline
- Start
- 2026-04-16
- Primary completion
- 2026-10-05
- Completion
- 2026-12-07
Publications
- Background Fahl WE. Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors. Arch Dermatol Res. 2016 Dec;308(10):751-757. doi: 10.1007/s00403-016-1691-2. Epub 2016 Oct 4.
- Background Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015 Jan 1;136(1):195-203. doi: 10.1002/ijc.28961. Epub 2014 May 16.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DA-020 | Unknown | 7 ml | Topical |
| Comparator | Hyperforin | Unknown | 1.5 % | Topical |